Last edition
News about "BioNTech"
The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.
BioNTech | 11/04/2026 | By News Bureau
BioNTech files patent lawsuit against Moderna over COVID-19 vaccine technology
German biotechnology firm BioNTech has filed a patent infringement lawsuit against U.S.-based vaccine maker Moderna in a federal court in Delaware. The case centers on Moderna’s updated COVID-19 vaccine, mNEXSPIKE, which BioNTech claims uses technology protected under its patents.
BioNTech | 20/02/2026 | By Darshana | 143
Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment
After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.
BioNTech | 14/11/2025 | By Darshana | 217
BioNTech and Duality Biologics reach major breakthrough in breast cancer trial
BioNTech and Duality Biologics have announced a significant advance in cancer drug development with the successful outcome of a Phase III trial for their investigational therapy BNT323, also known as trastuzumab pamirtecan.
BioNTech | 06/09/2025 | By Darshana | 209
Pfizer and BioNTech's Updated COVID-19 Vaccine Secures EMA Nod, Awaits Final EU Approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pfizer- BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine in the European Union.
BioNTech | 28/07/2025 | By Dineshwori | 218
BioNTech | 14/03/2023 | By Sudeep Soparkar | 796
BioNTech to invest $43 M in German facility for mRNA vaccine
With the facility, BioNTech is seeking more control over the supply chain
BioNTech | 04/02/2023 | By Sudeep Soparkar | 570
BioNTech | 15/11/2022 | By Sudeep Soparkar | 987
BioNTech 2nd phase of Covid 19 trials completed
The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine
BioNTech | 12/05/2022 | By Sudeep Soparkar | 738
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy